Dec 31, 2021

Alkermes Q4 2021 Earnings Report

Alkermes reported financial results for the fourth quarter and year ended Dec. 31, 2021.

Key Takeaways

Alkermes reported Q4 2021 revenues of $324.5 million and GAAP net income of $0.9 million, or $0.01 per share. Non-GAAP net income was $38.5 million, or $0.23 per share. The company provided financial expectations for 2022, reflecting a focus on proprietary products and continued operating efficiency.

Total revenues for the quarter were $324.5 million.

GAAP net income was $0.9 million for the quarter, or a basic and diluted GAAP earnings per share of $0.01.

Non-GAAP net income was $38.5 million for the quarter, or a non-GAAP basic earnings per share of $0.24 and diluted earnings per share of $0.23.

Alkermes recorded cash, cash equivalents and total investments of $765.7 million at Dec. 31, 2021.

Total Revenue
$324M
Previous year: $280M
+15.9%
EPS
$0.23
Previous year: $0.1
+130.0%
Gross Profit
$172M
Previous year: $125M
+38.0%
Cash and Equivalents
$338M
Previous year: $660M
-48.8%
Free Cash Flow
$22.4M
Previous year: $61.9M
-63.9%
Total Assets
$2.02B
Previous year: $1.95B
+3.8%

Alkermes

Alkermes

Alkermes Revenue by Segment

Forward Guidance

Alkermes provided financial expectations for 2022, assuming improvement in COVID-19 pandemic-related disruptions beginning in the second quarter and reflecting the removal of all royalties from worldwide sales of the long-acting INVEGA products beginning in 2022.

Revenue & Expenses

Visualization of income flow from segment revenue to net income